Table 2

Mean change in systolic blood pressure (SBP) from baseline to last follow-up among various subgroups

SubgroupStudiesMean difference in SBP (mm Hg)
I² (%)ES (95% CI)P value*
Gender0.80
 ≥35% female1178−21.82 (−29.76 to −13.88)
 <35% female1175−20.51 (−26.41 to −14.61)
Mean age (years) 0.03
 >251682−22.38 (−29.43 to −15.32)
 18–2550−24.96 (−29.90 to −20.02)
 <18455−14.93 (−20.61 to −9.25)
Native versus recurrent CoA <0.00001
 Only native863−28.99 (−35.36 to −22.63)
 ≥50% native1165−20.95 (−27.60 to −14.29)
 >50% recurrent40−12.76 (−17.48 to −8.05)
 Only recurrent222−5.43 (−11.20 to 0.34)
SBP baseline (mm Hg) 0.009
 >160679−32.77 (−47.07 to −18.47)
 140–1601765−19.64 (−23.42 to −15.87)
 <140360−9.22 (−17.09 to −1.36)
PSG baseline (mm Hg) <0.00001
 >401356−29.63 (−35.54 to −23.72)
 20–401120−16.21 (−18.75 to −13.67)
 <2020−4.55 (−9.85 to 0.76)
PSG poststenting (mm Hg)0.22
 >8369−27.39 (−47.90 to −6.87)
 4–8747−15.85 (−20.53 to −11.17)
 <41582−21.56 (−27.39 to −15.74)
Change in AHM use 0.004
 Reduction >25%60−27.97 (−32.79 to −23.14)
 Reduction ≤25%783−17.93 (−25.12 to −10.74)
 Increase or no change258−7.82 (−20.85 to 5.22)
 Follow-up duration (years)0.85
 >4337−20.66 (−31.08 to −10.23)
 2–41163−21.18 (−26.22 to −16.15)
 <21284−18.70 (−25.59 to −11.81)
Study design0.80
 Prospective cohort study1264−20.92 (−25.36 to −16.49)
 Retrospective cohort study1480−19.90 (−26.55 to −13.26)
Year of publication0.13
 2010–20181470−17.35 (−21.81 to −12.90)
 Prior to 20101278−23.74 (−30.72 to −16.76)
Method of BP measurement0.05
 24-hour ABPM258−7.82 (−20.85 to 5.22)
 Office BP2470−21.12 (−24.85 to −17.40)
Incomplete follow-up 0.79
 <5%1484−21.74 (−28.84 to −14.63)
 5%–20%748−18.68 (−23.83 to −13.53)
 >20%556−19.44 (−26.79 to −12.09)
  • Data are presented as mean difference (mm Hg) and 95% CI using a random-effects model. 

  • *Between subgroups; bold values indicate a statistically significant difference.

  • †Change in percentage of patients using any antihypertensive medication from baseline to last follow-up. 

  • ‡Percentage of patients with no available BP data ≥12 months after CoA stenting. 

  • ABPM, ambulatory blood pressure monitoring.; AHM, antihypertensive medication; BP, blood pressure; CoA, coarctation of the aorta; ES, effect size; PSG, peak systolic gradient across CoA site.